The peroxisome proliferator-activated receptor γ (PPARγ) ligands 15-deoxy-Δ12,14-prostaglandin J2 and ciglitazone induce human B lymphocyte and B cell lymphoma apoptosis by PPARγ-independent mechanisms

Journal of Immunology

Volumn 177, Issue 8, 2006, Pages 5068-5076

  Ray, Denise M ^a   Akbiyik, Filiz ^a,b   Phipps, Richard P ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b HACETTEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; 2 CHLORO 5 NITRO N (4 PYRIDYL)BENZAMIDE; 2 CHLORO 5 NITROBENZANILIDE; CAY 10410; CIGLITAZONE; GLUTATHIONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; REACTIVE OXYGEN METABOLITE; TROGLITAZONE; UNCLASSIFIED DRUG;

ADIPOGENESIS; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CELL VIABILITY; CONTROLLED STUDY; DRUG STRUCTURE; HUMAN; HUMAN CELL; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL MEMBRANE POTENTIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION;

EID: 33749506249     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.177.8.5068     Document Type: Article

References (50)

1. Daynes, R. A., and D. C. Jones. 2002. Emerging roles of PPARs in inflammation and immunity. Nat. Rev. Immunol. 2: 748-759.
2. Kliewer, S. A., K. Umesono, D. J. Noonan, R. A. Heyman, and R. M. Evans. 1992. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 358: 771-774.
3. Zhu, Y., C. Qi, J. R. Korenberg, X. N. Chen, D. Noya, M. S. Rao, and J. K. Reddy. 1995. Structural organization of mouse peroxisome proliferator- activated receptor γ (mPPAR γ) gene: alternative promoter use and different splicing yield two mPPAR γ isoforms. Proc. Natl. Acad. Sci. USA 92: 7921-7925.
4. Yanase, T., T. Yashiro, K. Takitani, S. Kato, S. Taniguchi, R. Takayanagi, and H. Nawata. 1997. Differential expression of PPARγ1 and γ2 isoforms in human adipose tissue. Biochem. Biophys. Res. Commun. 233: 320-324.
5. Fajas, L., D. Auboeuf, E. Raspe, K. Schoonjans, A. M. Lefebvre, R. Saladin, J. Najib, M. Laville, J. C. Fruchart, S. Deeb, et al. 1997. The organization, promoter analysis, and expression of the human PPARγ gene. J. Biol. Chem. 272: 18779-18789.
6. Marx, N., T. Bourcier, G. K. Sukhova, P. Libby, and J. Plutzky. 1999. PPARγ activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARγ as a potential mediator in vascular disease. Arterioscler. Thromb. Vasc. Biol. 19: 546-551.
7. Lee, Y., T. S. Huang, M. L. Yang, L. R. Huang, C. H. Chen, and F. J. Lu. 1999. Peroxisome proliferation, adipocyte determination and differentiation of C3H10T1/2 fibroblast cells induced by humic acid: induction of PPAR in diverse cells. J. Cell. Physiol. 179: 218-225.
8. Ricote, M., A. C. Li, T. M. Willson, C. J. Kelly, and C. K. Glass. 1998. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 391: 79-82.
9. Nencioni, A., K. Lauber, F. Grunebach, W. Brugger, C. Denzlinger, S. Wesselborg, and P. Brossart. 2002. Cyclopentenone prostaglandins induce caspase activation and apoptosis in dendritic cells by a PPAR-γ-independent mechanism: regulation by inflammatory and T cell-derived stimuli. Exp. Hematol. 30: 1020-1028.
10. Harris, S. G., and R. P. Phipps. 2001. The nuclear receptor PPAR γ is expressed by mouse T lymphocytes and PPAR γ agonists induce apoptosis. Eur. J. Immunol. 31: 1098-1105.
11. 2 induce apoptosis in normal and malignant B-lineage cells. J. Immunol. 165: 6941-6948.
12. Padilla, J., E. Leung, and R. P. Phipps. 2002. Human B lymphocytes and B lymphomas express PPAR-γ and are killed by PPAR-γ agonists. Clin. Immunol. 103: 22-33.
13. Koshiyama, H., D. Shimono, N. Kuwamura, J. Minamikawa, and Y. Nakamura. 2001. Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J. Clin. Endocrinol. Metab. 86: 3452-3456.
14. Lehmann, J. M., L. B. Moore, T. A. Smith-Oliver, W. O. Wilkison, T. M. Willson, and S. A. Kliewer. 1995. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPAR γ). J. Biol. Chem. 270: 12953-12956.
15. Su, C. G., X. Wen, S. T. Bailey, W. Jiang, S. M. Rangwala, S. A. Keilbaugh, A. Flanigan, S. Murthy, M. A. Lazar, and G. D. Wu. 1999. A novel therapy for colitis utilizing PPAR-γ ligands to inhibit the epithelial inflammatory response. J. Clin. Invest. 104: 383-389.
16. 2 is a ligand for the adipocyte determination factor PPAR γ. Cell 83: 803-812.
17. 2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell 83: 813-819.
18. McIntyre, T. M., A. V. Pontsler, A. R. Silva, A. St Hilaire, Y. Xu, J. C. Hinshaw, G. A. Zimmerman, K. Hama, J. Aoki, H. Arai, and G. D. Prestwich. 2003. Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARγ agonist. Proc. Natl. Acad. Sci. USA 100: 131-136.
19. Schopfer, F. J., Y. Lin, P. R. Baker, T. Cui, M. Garcia-Barrio, J. Zhang, K. Chen, Y. E. Chen, and B. A. Freeman. 2005. Nitrolinoleic acid: an endogenous peroxisome proliferator-activated receptor γ ligand. Proc. Natl. Acad. Sci. USA 102: 2340-2345.
20. Tontonoz, P., E. Hu, and B. M. Spiegelman. 1994. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor. Cell 79: 1147-1156.
21. 2 and related compounds: an update. Prostaglandins Leukot. Essent. Fatty Acids 47: 1-12.
22. Christ-Hazelhof, E., and D. H. Nugteren. 1979. Purification and characterisation of prostaglandin endoperoxide D-isomerase, a cytoplasmic, glutathione-requiring enzyme. Biochim. Biophys. Acta 572: 43-51.
23. Urade, Y., N. Fujimoto, and O. Hayaishi. 1985. Purification and characterization of rat brain prostaglandin D synthetase. J. Biol. Chem. 260: 12410-12415.
24. 2 generation after activation of rat and human mast cells with anti-IgE. J. Immunol. 129: 1627-1631.
25. 2 production is likely antigen-presenting cells: localization of glutathione-requiring prostaglandin D synthetase in histiocytes, dendritic, and Kupffer cells in various rat tissues. J. Immunol. 143: 2982-2989.
26. 2 by human helper T cell subsets. J. Immunol. 164: 2277-2280.
27. 2 metabolite generated during inflammatory processes. J. Biol. Chem. 277: 10459-10466.
28. Gilroy, D. W., P. R. Colville-Nash, D. Willis, J. Chivers, M. J. Paul-Clark, and D. A. Willoughby. 1999. Inducible cyclooxygenase may have anti-inflammatory properties. Nat. Med. 5: 698-701.
29. Kim, J., P. Yang, M. Suraokar, A. L. Sabichi, N. D. Llansa, G. Mendoza, V. Subbarayan, C. J. Logothetis, R. A. Newman, S. M. Lippman, and D. G. Menter. 2005. Suppression of prostate tumor cell growth by stromal cell prostaglandin D synthase-derived products. Cancer Res. 65: 6189-6198.
30. 2 inhibits multiple steps in the NF-κB signaling pathway. Proc. Natl. Acad. Sci. USA 97: 4844-4849.
31. 2 inhibition of NF-κB-DNA binding through covalent modification of the p50 subunit. J. Biol. Chem. 276: 35530-35536.
32. 2-anti-tumour and anti-viral activities and the mechanisms involved. Eicosanoids 3: 189-199.
33. 2-induced apoptosis does not require PPARγ in breast cancer cells. J. Lipid Res. 43: 1818-1828.
34. 2 induces apoptosis of human hepatic myofibroblasts: a pathway involving oxidative stress independently of peroxisome-proliferator-activated receptors. J. Biol. Chem. 276: 38152-38158.
35. Jiang, C., A. T. Ting, and B. Seed. 1998. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 391: 82-86.
36. Chawla, A., Y. Barak, L. Nagy, D. Liao, P. Tontonoz, and R. M. Evans. 2001. PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat. Med. 7: 48-52.
37. Kelly, D., J. I. Campbell, T. P. King, G. Grant, E. A. Jansson, A. G. Coutts, S. Pettersson, and S. Conway. 2004. Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-γ and RelA. Nat. Immunol. 5: 104-112.
38. Chung, S. W., B. Y. Kang, S. H. Kim, Y. K. Pak, D. Cho, G. Trinchieri, and T. S. Kim. 2000. Oxidized low density lipoprotein inhibits interleukin-12 production in lipopolysaccharide-activated mouse macrophages via direct interactions between peroxisome proliferator-activated receptor-γ and nuclear factor-κ B. J. Biol. Chem. 275: 32681-32687.
39. Barak, Y., M. C. Nelson, E. S. Ong, Y. Z. Jones, P. Ruiz-Lozano, K. R. Chien, A. Koder, and R. M. Evans. 1999. PPAR κ is required for placental, cardiac, and adipose tissue development. Mol. Cell 4: 585-595.
40. Setoguchi, K., Y. Misaki, Y. Terauchi, T. Yamauchi, K. Kawahata, T. Kadowaki, and K. Yamamoto. 2001. Peroxisome proliferator-activated receptor-γ haploinsufficiency enhances B cell proliferative responses and exacerbates experimentally induced arthritis. J. Clin. Invest. 108: 1667-1675.
41. Ray, D. M., S. H. Bernstein, and R. P. Phipps. 2004. Human multiple myeloma cells express peroxisome proliferator-activated receptor γ and undergo apoptosis upon exposure to PPARγ ligands. Clin. Immunol. 113: 203-213.
42. Gurnell, M., J. M. Wentworth, M. Agostini, M. Adams, T. N. Collingwood, C. Provenzano, P. O. Browne, O. Rajanayagam, T. P. Burris, J. W. Schwabe, et al. 2000. A dominant-negative peroxisome proliferator-activated receptor γ (PPARγ) mutant is a constitutive repressor and inhibits PPARγ-mediated adipogenesis. J. Biol. Chem. 275: 5754-5759.
43. Hempel, S. L., G. R. Buettner, Y. Q. O'Malley, D. A. Wessels, and D. M. Flaherty. 1999. Dihydrofluorescein diacetate is superior for detecting intracellular oxidants: comparison with 2′,7′- dichlorodihydrofluorescein diacetate, 5(and 6)-carboxy-2′,7′- dichlorodihydrofluorescein diacetate, and dihydrorhodamine 123. Free Radic. Biol. Med. 27: 146-159.
44. Leesnitzer, L. M., D. J. Parks, R. K. Bledsoe, J. E. Cobb, J. L. Collins, T. G. Consler, R. G. Davis, E. A. Hull-Ryde, J. M. Lenhard, L. Patel, et al. 2002. Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry 41: 6640-6650.
45. Lee, G., F. Elwood, J. McNally, J. Weiszmann, M. Lindstrom, K. Amaral, M. Nakamura, S. Miao, P. Cao, R. M. Learned, et al. 2002. T0070907, a selective ligand for peroxisome proliferator-activated receptor γ, functions as an antagonist of biochemical and cellular activities. J. Biol. Chem. 277: 19649-19657.
46. Kondo, M., T. Oya-Ito, T. Kumagai, T. Osawa, and K. Uchida. 2001. Cyclopentenone prostaglandins as potential inducers of intracellular oxidative stress. J. Biol. Chem. 276: 12076-12083.
47. 2. Biochemistry 29: 3760-3765.
48. Shibata, T., T. Yamada, T. Ishii, S. Kumazawa, H. Nakamura, H. Masutani, J. Yodoi, and K. Uchida. 2003. Thioredoxin as a molecular target of cyclopentenone prostaglandins. J. Biol. Chem. 278: 26046-26054.
49. Byung, P. L. 1994. Cellular defenses against damage from reactive oxygen species. Physiol. Rev. 74: 139-162.
50. Ray, D. M., F. Akbiyik, S. H. Bernstein, and R. P. Phipps. 2005. CD40 engagement prevents peroxisome proliferator-activated receptor γ agonist-induced apoptosis of B lymphocytes and B lymphoma cells by an NF-κB-dependent mechanism. J. Immunol. 174: 4060-4069.